Can a common heart drug prevent bleeding in cirrhosis?

NCT ID NCT06861075

Recruiting now Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether carvedilol, a beta-blocker, can reduce high blood pressure in the liver's portal vein in people with cirrhosis. High pressure can lead to dangerous bleeding. Researchers will use an endoscopic ultrasound to measure pressure before and after one month of treatment. The trial enrolls 30 adults with cirrhosis and suspected portal hypertension.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carvedilol (a beta-blocker drug)
What this could lead to: If it works, this could provide a simple way to measure and reduce bleeding risk in people with cirrhosis.
What could go wrong: This is a small, early-phase study with only 30 people. The drug may not lower pressure enough, and side effects like dizziness or fatigue are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS PORTAL HYPERTENSION RELATED TO CIRRHOSIS

Contacts and locations

Locations

Chu Estaing Medecine Digestive Et Hepatobiliaire
RECRUITING

Clermont-Ferrand, 63003, France
Lise Laclautre
NOT_YET_RECRUITING

Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.